Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'

Br J Cancer. 2013 May 28;108(10):2192-3. doi: 10.1038/bjc.2013.210. Epub 2013 Apr 30.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal